Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Pegfilgrastim Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.296

    Pegfilgrastim and Pegfilgrastim Biosimilars

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.296 alerts

    Get alerted when Policy AZ.CP.PHAR.296 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Arizona Medicaid coverage and prior authorization for pegfilgrastim products used for FDA-approved indications and specified off-label oncology or transplantation uses.

    Policy Summary
    PayerArizona Complete Health
    PolicyPegfilgrastim and Pegfilgrastim Biosimilars
    Policy CodePolicy AZ.CP.PHAR.296
    Change TypeModified
    Effective DateApr 1, 2020
    Last ReviewAug 1, 2021
    Next Review DateN/A
    Key ActionFor Neulasta or Ziextenzo requests, document failure of Fulphila, Nyvepria, and Udenyca unless a preferred product is contraindicated or caused clinically significant adverse effects.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added the pegfilgrastim biosimilar Nyvepria to the policy.

    The policy added a requirement to confirm that at least 12 days separate a pegfilgrastim dose from the next chemotherapy cycle.

    Preferred colony-stimulating-factor updates made Nyvepria preferred and required Neulasta and Ziextenzo requests to demonstrate failure of Fulphila, Nyvepria, and Udenyca unless contraindicated or clinically significant adverse effects occurred.

    The policy removed the requirement for specified Acute Radiation Syndrome and bone marrow transplantation indications to use particular preferred products.

    The policy added NCCN Compendium-supported off-label indications.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5Pegfilgrastim products addressed
    3AHCCCS preferred products
    2AHCCCS non-preferred products
    6 monthsStandard approval duration
    12 daysMinimum chemotherapy-cycle interval
    4HCPCS codes listed

    Coverage Criteria

    Chemotherapy-Induced Neutropenia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of a non-myeloid malignancy.
    • Prescribed for use following myelosuppressive chemotherapy.
    • For Neulasta or Ziextenzo requests, the member has failed Fulphila, Nyvepria, and Udenyca, unless contraindicated or clinically significant adverse effects were experienced.

      Prior authorization may be required for Fulphila, Nyvepria, and Udenyca.

    • There are at least 12 days between the pegfilgrastim dose and the next cycle of chemotherapy.>= 12 days
    • For members receiving palliative chemotherapy, the provider attests that chemotherapy dose reduction has been considered.
    • Dose does not exceed 6 mg (1 syringe) per chemotherapy cycle.<= 6 mg per cycle

    Acute Radiation Syndrome

    Covered when ALL of the following are met:

    ALL of the following

    • Prescribed following suspected or confirmed acute exposure to myelosuppressive doses of radiation.
    • For Neulasta or Ziextenzo requests, the member has failed Fulphila, Nyvepria, and Udenyca, unless contraindicated or clinically significant adverse effects were experienced.

      Prior authorization may be required for Fulphila, Nyvepria, and Udenyca.

    • Dose does not exceed two 6 mg doses administered one week apart.2 doses of 6 mg, 1 week apart

    Bone Marrow Transplantation (Off-Label)

    Covered off-label when ALL of the following are met:

    ALL of the following

    • ONE of

      • Supportive care following autologous hematopoietic cell transplantation.
      • Mobilization of peripheral-blood progenitor cells before autologous transplantation.
    • For Neulasta or Ziextenzo requests, the member has failed Fulphila, Nyvepria, and Udenyca, unless contraindicated or clinically significant adverse effects were experienced.

      Prior authorization may be required for Fulphila, Nyvepria, and Udenyca.

    • ONE of

      • Dose does not exceed 6 mg per dose.

    Wilms Tumor (Off-Label)

    Covered off-label when ALL of the following are met:

    ALL of the following

    • Diagnosis of Wilms tumor (nephroblastoma).
    • Request is for supportive care for a member receiving a regimen of cyclophosphamide and etoposide, or cyclophosphamide, doxorubicin, and vincristine in Regimen M or Regimen I.
    • Request is for treatment associated with Stage IV or metastatic cancer in a state with regulations against step therapy in advanced oncology settings.
    • For Neulasta or Ziextenzo requests, the member has failed Fulphila, Nyvepria, and Udenyca, unless contraindicated or clinically significant adverse effects were experienced.

      Prior authorization may be required for Fulphila, Nyvepria, and Udenyca.

    • ONE of

    Continued Therapy

    Continuation therapy for all Section I indications requires ALL of the following:

    ALL of the following

    • Currently receiving the medication through a Centene benefit, or the member previously met the initial approval criteria.
    • Member is responding positively to therapy.
    • For Neulasta or Ziextenzo requests, the member has failed Fulphila, Nyvepria, and Udenyca, unless contraindicated or clinically significant adverse effects were experienced.

      Prior authorization may be required for Fulphila, Nyvepria, and Udenyca.

    • Dose increase does not exceed ONE of the following

      • Chemotherapy-induced neutropenia: 6 mg (1 syringe) administered once per chemotherapy cycle.<= 6 mg per cycle

    Other Diagnoses or Indications

    Coverage requires ONE of the following:

    ONE of

    • Currently receiving the medication through a Centene benefit, with documentation supporting a positive response to therapy.

      Approval duration is the duration of the request or 6 months, whichever is less.

    • For a diagnosis not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid.

    Myelosuppressive Chemotherapy

    Covered dosing criteria:

    ALL of the following

    • Pegfilgrastim products are administered subcutaneously at 6 mg once per chemotherapy cycle.6 mg SC once per cycle
    • For pediatric patients weighing less than 45 kg, use weight-based dosing.
    • Dose does not exceed 6 mg per dose.<= 6 mg per dose

    Acute Radiation Syndrome

    Covered dosing criteria for acute radiation exposure:

    ALL of the following

    • Neulasta is administered as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation.
    • Administer two 6 mg doses subcutaneously one week apart.2 doses of 6 mg, 1 week apart
    • For pediatric patients weighing less than 45 kg, use weight-based dosing.
    • Dose does not exceed 6 mg per dose.<= 6 mg per dose

    Supported Additional Indications

    Supported additional indications may be covered when the requested use is supported by applicable clinical evidence or compendia:

    ONE of

    • Supportive care following autologous hematopoietic cell transplantation, supported by the NCCN Compendium (category 2A).
    • Mobilization of peripheral blood stem cells before autologous stem-cell transplantation, supported by DRUGDEX (Class IIa recommendation).
    • Supportive care for Wilms tumor chemotherapy regimens supported by the clinical information in this policy: Regimen M includes vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide; Regimen I includes vincristine, doxorubicin, cyclophosphamide, and etoposide.

    Fulphila, Neulasta, Nyvepria, Udenyca, and Ziextenzo are not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

    Non-FDA-approved indications that are not addressed in this policy are excluded unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy, including AZ.CP.PMN.53 for Arizona Medicaid, or the applicable evidence of coverage documents.

    Coverage is excluded for members with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as pegfilgrastim or filgrastim products.

    Do not administer pegfilgrastim between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

    Initial Therapy Criteria

    Initial Chemotherapy-Induced Neutropenia

    Initial therapy for chemotherapy-induced neutropenia requires ALL criteria.

    Chemotherapy-Induced Neutropenia: The member has a non-myeloid malignancy; pegfilgrastim is prescribed following myelosuppressive chemotherapy; for Neulasta or Ziextenzo, Fulphila, Nyvepria, and Udenyca have failed unless contraindicated or associated with clinically significant adverse effects; there are at least 12 days before the next chemotherapy cycle; for palliative chemotherapy, the provider attests that chemotherapy dose reduction has been considered; and the dose does not exceed 6 mg per cycle.At least 12 days; maximum 6 mg per cycle

    Approval duration is 6 months.

    Initial Acute Radiation Syndrome

    Initial therapy for acute radiation syndrome requires ALL criteria.

    Acute Radiation Syndrome: The member has suspected or confirmed acute exposure to myelosuppressive doses of radiation; for Neulasta or Ziextenzo, Fulphila, Nyvepria, and Udenyca have failed unless contraindicated or associated with clinically significant adverse effects; and the dose does not exceed two 6 mg doses administered one week apart.

    Continuation Therapy

    Continuation Therapy

    Continued therapy requires ALL of the following.

    Continuation: The member is receiving the medication through a Centene benefit or previously met initial criteria; the member is responding positively to therapy; for Neulasta or Ziextenzo, Fulphila, Nyvepria, and Udenyca have failed unless contraindicated or associated with clinically significant adverse effects; and any dose increase remains within the applicable indication-specific limits.6 months approval duration

    Chemotherapy-induced neutropenia: 6 mg once per cycle; acute radiation syndrome: two 6 mg doses one week apart; bone marrow transplantation: 6 mg per dose unless evidence supports an alternative dose.

    Preferred Biosimilar Step Therapy

    StepPreferred productsTarget productsRequirement
    1Fulphila, Nyvepria, and UdenycaNeulasta or ZiextenzoDocument failure of all preferred products before requesting the target product, unless a preferred product is contraindicated or caused clinically significant adverse effects.
    StepPreferred productsTarget productsRequirement
    1Fulphila, Nyvepria, and UdenycaNeulasta or ZiextenzoUse the preferred products before requesting Neulasta or Ziextenzo; document failure, contraindication, or clinically significant adverse effects associated with the preferred products.

    Quantity and Dose Limits

    Chemotherapy-Induced Neutropenia
    IndicationChemotherapy-induced neutropenia
    Maximum quantity6 mg (1 syringe) per chemotherapy cycle
    Timing requirementAt least 12 days must separate the pegfilgrastim dose from the next chemotherapy cycle
    Acute Radiation Syndrome
    IndicationAcute radiation syndrome following suspected or confirmed exposure to myelosuppressive radiation
    Maximum quantityTwo 6 mg doses
    Administration interval

    Coding and Clinical Dose Parameters

    HCPCS CodesHCPCS
    J2505Injection, pegfilgrastim, 6 mg
    Q5111Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg
    Q5108Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg
    Q5120Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo), 0.5 mg
    Interval Before Next Chemotherapy Cycle
    IntervalAt least 12 days
    Measured betweenPegfilgrastim dose and the next chemotherapy cycle
    DocumentationThe request must confirm that the interval is met
    Chemotherapy-Induced Neutropenia Dose
    IndicationChemotherapy-induced neutropenia
    Dose6 mg (1 syringe) per chemotherapy cycle
    Dose increase limitA continued-therapy dose increase must remain within 6 mg once per chemotherapy cycle

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for requests under this policy and may also be required for preferred products Fulphila, Nyvepria, and Udenyca.

    • Submit the request with all required clinical and product-selection information.
    Step Therapy

    Product Selection Required

    Requests for pegfilgrastim products must meet the applicable product-selection requirements before authorization.

    • Apply the preferred-product sequence before requesting Neulasta or Ziextenzo.
    Step Therapy

    Clinical Background

    Pegfilgrastim products are leukocyte growth factors used to reduce infection manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer therapy. Neulasta is also indicated to increase survival after acute exposure to myelosuppressive doses of radiation causing the hematopoietic subsyndrome of acute radiation syndrome.

    Definitions and Abbreviations

    Definitions
    AbbreviationANC
    MeaningAbsolute neutrophil count
    Clinical relevanceANC is used in the policy’s definition of neutropenia
    Definitions
    AbbreviationASCO
    Full nameAmerican Society of Clinical Oncology
    CategoryOncology organization

    Pegfilgrastim Product Preferences

    Billing Rule

    Neulasta requires preferred-product failure

    Neulasta is an AHCCCS preferred product. Failure of the other preferred products is required before a Neulasta request unless they are contraindicated or associated with clinically significant adverse effects.

    Billing Rule

    Document failure before requesting Neulasta

    Neulasta is an AHCCCS preferred product. Failure of Fulphila, Nyvepria, and Udenyca is required before requesting Neulasta unless a preferred product is contraindicated or associated with clinically significant adverse effects.

    Billing Rule

    Apply Neulasta sequencing requirements

    Policy Summary
    PayerArizona Complete Health
    PolicyPegfilgrastim and Pegfilgrastim Biosimilars
    Policy CodePolicy AZ.CP.PHAR.296
    Change TypeModified
    Effective DateApr 1, 2020
    Last ReviewAug 1, 2021
    Next Review DateN/A
    Key ActionFor Neulasta or Ziextenzo requests, document failure of Fulphila, Nyvepria, and Udenyca unless a preferred product is contraindicated or caused clinically significant adverse effects.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation TherapyPreferred Biosimilar Step TherapyQuantity and Dose LimitsCoding and Clinical Dose ParametersAuthorization and Documentation RequirementsClinical BackgroundDefinitions and AbbreviationsPegfilgrastim Product Preferences
    <= 6 mg per dose
  1. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

    The prescriber must submit supporting evidence.

  2. Dose does not exceed 6 mg (1 syringe) per chemotherapy cycle.<= 6 mg per cycle
  3. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

    The prescriber must submit supporting evidence.

  4. Acute radiation syndrome: two 6 mg doses administered one week apart.2 doses of 6 mg, 1 week apart
  5. Bone marrow transplantation: 6 mg (1 syringe) per dose, or a dose supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

    The prescriber must submit supporting evidence.

  6. Two 6 mg doses one week apart

    Approval duration is 6 months.

    Initial Bone Marrow Transplantation

    Initial therapy for off-label bone marrow transplantation requires ALL criteria.

    Bone Marrow Transplantation: The request is for supportive care after autologous hematopoietic cell transplantation OR mobilization before autologous transplantation; for Neulasta or Ziextenzo, Fulphila, Nyvepria, and Udenyca have failed unless contraindicated or associated with clinically significant adverse effects; and the dose does not exceed 6 mg per dose OR is supported by practice guidelines or peer-reviewed literature with prescriber-submitted evidence.6 mg per dose unless supported by evidence

    Approval duration is 6 months.

    Initial Wilms Tumor

    Initial therapy for off-label Wilms tumor requires ALL criteria.

    Wilms Tumor: The member has Wilms tumor; therapy is supportive care with the specified cyclophosphamide/etoposide or cyclophosphamide/doxorubicin/vincristine Regimen M or Regimen I; treatment is for Stage IV or metastatic disease in a state with applicable regulations against step therapy in advanced oncology settings; for Neulasta or Ziextenzo, Fulphila, Nyvepria, and Udenyca have failed unless contraindicated or associated with clinically significant adverse effects; and the dose does not exceed 6 mg per cycle OR is supported by practice guidelines or peer-reviewed literature with prescriber-submitted evidence.6 mg per cycle unless supported by evidence

    Approved duration is 6 months.

    Preferred Product Requirement

    Initial requests for selected products require ALL of the following.

    Preferred-Product Sequencing: Requests for Neulasta or Ziextenzo must document failure of Fulphila, Nyvepria, and Udenyca unless a preferred product is contraindicated or caused clinically significant adverse effects.

    Nyvepria is a preferred product.

    The two doses are administered one week apart
    Bone Marrow Transplantation
    IndicationBone marrow transplantation supportive care or peripheral-blood progenitor-cell mobilization before autologous transplantation
    Standard quantity6 mg per dose
    Alternative dosingA higher or different dose may be used when supported by practice guidelines or peer-reviewed literature and submitted with supporting evidence
    Pegfilgrastim Dose
    MedicationPegfilgrastim products
    Dose6 mg
    FrequencyOnce per chemotherapy cycle
    Acute Radiation Exposure
    IndicationAcute exposure to myelosuppressive doses of radiation
    DoseTwo 6-mg doses
    TimingAdminister the first dose as soon as possible after suspected or confirmed exposure and the second dose one week later
    Acute Radiation Syndrome Dose
    IndicationAcute radiation syndrome
    DoseTwo 6 mg doses
    Administration scheduleDoses are administered one week apart
    Bone Marrow Transplantation Dose
    IndicationBone marrow transplantation
    Standard dose6 mg per dose
    Evidence-supported alternativeA higher or different dose is permitted when supported by practice guidelines or peer-reviewed literature, with supporting evidence submitted by the prescriber
    High-Risk Febrile-Neutropenia Threshold
    Risk categoryHigh risk for febrile neutropenia
    ThresholdGreater than 20% incidence of febrile neutropenia
    Population referencedChemotherapy-naive patients in clinical trials
    Intermediate-Risk Febrile-Neutropenia Threshold
    Risk categoryIntermediate risk for febrile neutropenia
    Threshold10% to 20% overall risk of febrile neutropenia
    Recommendation contextNCCN Compendium recommends that prophylaxis be considered at this risk level

    Preferred Biosimilar Trial

    Before requesting Neulasta or Ziextenzo, document failure of the preferred biosimilars Fulphila, Nyvepria, and Udenyca, unless a product is contraindicated or caused clinically significant adverse effects.

    • Document the trial and outcome for each preferred biosimilar, or the applicable exception.
    Step Therapy

    Preferred Biosimilar Sequence

    Use preferred pegfilgrastim products before requesting Neulasta or Ziextenzo.

    • Preferred sequence: Fulphila, Nyvepria, and Udenyca before Neulasta or Ziextenzo.
    • Neulasta or Ziextenzo requests require documented failure of preferred products unless an exception applies.
    Documentation Required

    Clinical Documentation Required

    Submit documentation supporting that the member meets all approval criteria.

    • Include office chart notes, laboratory results, or other relevant clinical information.
    Documentation Required

    Support Off-Label Requests

    For off-label requests, submit supporting evidence when required by the criteria.

    • Provide applicable practice guidelines or peer-reviewed literature supporting the dose or relevant off-label use.
    Documentation Required

    Palliative Chemotherapy Attestation

    For members receiving palliative chemotherapy, attest that chemotherapy dose reduction has been considered.

    • Include the attestation with the authorization request.
    Denial Risk

    Chemotherapy-Cycle Interval

    Confirm that there are at least 12 days between the pegfilgrastim dose and the next chemotherapy cycle.

    • Requests may be denied when the required interval is not documented.
    Documentation Required

    Preferred-Product History

    For Neulasta or Ziextenzo, document failure of Fulphila, Nyvepria, and Udenyca, or document that a preferred product is contraindicated or caused clinically significant adverse effects.

    • Include the preferred-product history and the reason for any exception.
    Documentation Required

    Unaddressed Non-FDA Indications

    For non-FDA-approved indications not addressed by this policy, coverage requires sufficient documentation of efficacy and safety under the applicable off-label use policy or evidence of coverage document.

    • Submit supporting efficacy and safety evidence for the requested use.
    Denial Risk

    Failure to Use Preferred Biosimilar

    Neulasta or Ziextenzo requests require documentation explaining why the preferred biosimilars were not used.

    • Document failure of Fulphila, Nyvepria, and Udenyca, or a contraindication or clinically significant adverse effect.
    Denial Risk

    Dose and Timing Limits

    Requests may be denied if the dose exceeds the policy limit or if fewer than 12 days are documented between the pegfilgrastim dose and the next chemotherapy cycle.

    • Chemotherapy-induced neutropenia: maximum 6 mg (one syringe) per chemotherapy cycle.
    • Confirm the required interval between dose and the next cycle.
    Denial Risk

    Serious G-CSF Allergy

    A history of serious allergic reactions to human granulocyte colony-stimulating factors, including pegfilgrastim or filgrastim products, is a contraindication and may result in denial.

    • Review and document relevant allergy history before requesting or administering therapy.
    Step Therapy

    Preferred-Product Failure Requirement

    Neulasta or Ziextenzo requires failure of Fulphila, Nyvepria, and Udenyca unless a preferred product is contraindicated or caused clinically significant adverse effects.

    • Do not bypass the preferred-product requirement without documenting the applicable exception.
    Denial Risk

    Improper Chemotherapy Timing

    For myelosuppressive chemotherapy, do not administer pegfilgrastim from 14 days before through 24 hours after administration of cytotoxic chemotherapy.

    • Schedule administration once the required chemotherapy interval is met.
    • The usual regimen is 6 mg subcutaneously once per chemotherapy cycle, subject to policy criteria.
    Definitions
    AbbreviationCSFs
    Full nameColony-stimulating factors
    Clinical classColony-stimulating factors are referenced in the policy’s oncology supportive-care context
    Definitions
    TermNeutropenia
    Primary definitionAbsolute neutrophil count below 500 neutrophils/mcL
    Alternative definitionANC below 1,000 neutrophils/mcL with a predicted decline to 500 neutrophils/mcL or less over the next 48 hours
    Definitions
    TermFebrile neutropenia
    Single-temperature definitionA single oral temperature of at least 38.8°C
    Sustained-temperature definitionA temperature of at least 38.0°C sustained over 1 hour
    Definitions
    AbbreviationNCCN
    Full nameNational Comprehensive Cancer Network
    Policy roleThe NCCN panel identifies chemotherapy regimens with greater than 20% febrile-neutropenia incidence as high risk and supports prophylaxis recommendations

    Neulasta is an AHCCCS preferred product, but requests must still document failure of Fulphila, Nyvepria, and Udenyca unless those products are contraindicated or caused clinically significant adverse effects.

    Billing Rule

    Neulasta is non-preferred

    Neulasta is an AHCCCS non-preferred product. Failure of Fulphila, Nyvepria, and Udenyca is required unless a preferred product is contraindicated or associated with clinically significant adverse effects.

    Billing Rule

    Nyvepria is now preferred

    Nyvepria was moved from non-preferred to preferred. Use it as a preferred product when applying the policy’s product-selection requirements.

    Billing Rule

    Preferred products precede Neulasta and Ziextenzo

    Neulasta and Ziextenzo requests require failure of the preferred products Fulphila, Nyvepria, and Udenyca unless a preferred product is contraindicated or associated with clinically significant adverse effects.